First Trust NYSE Arca Biotechnology ETF

(fka First Trust AlphaDEX™ U.S. Materials Sector Index ETF)

Ticker: FBT

Quarter End Statement of Investments

3rd Quarter as at September 30, 2024



Sector Allocation	% of Net Asset Value
Exchange-Traded Fund (First Trust NYSE® Arca® Biotechnology Index Fund ["Underlying Fund"])* Cash and Cash Equivalents	99.97% 0.03%
Total Other Assets and Liabilities	100.00%
Total Net Asset Value	100.00%

Industry Allocation 9 of the Underlying Fund	6 of Net Asset Value of the Underlying Fund
Biotechnology Life Sciences Tools & Services	74.94% 17.59%
Pharmaceuticals Cash and Cash Equivalents	7.47% 0.08%
Total Other Assets and Liabilities	100.08% (0.08%)
Total Net Asset Value of the Underlying F	und 100.00%

Country Allocation of the Underlying Fund	% of Net Asset Value of the Underlying Fund
United States	80.99%
Cayman Islands	4.58%
Germany	4.34%
Ireland	3.68%
Netherlands	3.61%
Denmark	2.80%

Holdings	% of Net Asset Value
First Trust NYSE® Arca® Biotechnology Index Fund	99.97%
Total Net Asset Value	\$1,749,992

Top 25 Holdings of the Underlying Fund	% of Net Asset Value of the Underlying Fund
BeiGene Ltd. (ADR)	4.58%
Corcept Therapeutics, Inc.	4.56%
Exact Sciences Corporation	4.56%
BioNTech SE (ADR)	4.34%
Catalyst Pharmaceuticals, Inc.	3.72%
Gilead Sciences, Inc.	3.72%
Alkermes Plc	3.69%
Waters Corporation	3.69%
Repligen Corporation	3.67%
argenx SE (ADR)	3.61%
Exelixis, Inc.	3.60%
Natera, Inc.	3.53%
Illumina, Inc.	3.49%
United Therapeutics Corporation	3.46%
Mettler-Toledo International, Inc.	3.43%
Halozyme Therapeutics, Inc.	3.34%
Bruker Corporation	3.31%
Alnylam Pharmaceuticals, Inc.	3.28%
Incyte Corporation	3.22%
Amgen, Inc.	3.02%
Regeneron Pharmaceuticals, Inc.	2.97%
Vertex Pharmaceuticals, Inc.	2.95%
Intra-Cellular Therapies, Inc.	2.91%
Genmab A/S (ADR)	2.80%
ACADIA Pharmaceuticals, Inc.	2.69%
Total Net Asset Value of the Underlying Fund (in U	SD) \$1,205,938,267

Commissions, management fees and expenses all may be associated with ETF investments. Please carefully read the simplified prospectus of the ETF before investing. ETFs are not guaranteed, their values change frequently and past performance may not be repeated. Data is as of September 30, 2024 (unaudited).

^{*}The First Trust ETF obtains exposure to the performance of an index of U.S. companies in the biotechnology industry, initially the NYSE® Arca Biotechnology Index (the "Index") by investing in the Underlying Fund, a U.S.-listed index fund (i.e. First Trust NYSE® Arca® Biotechnology Index Fund [the "Underlying Fund"]) which itself replicates or substantially replicates the Index.